Ritter Daniher Financial Advisory LLC DE Grows Stock Position in Johnson & Johnson (NYSE:JNJ)

Ritter Daniher Financial Advisory LLC DE grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 24.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 863 shares of the company’s stock after acquiring an additional 171 shares during the quarter. Ritter Daniher Financial Advisory LLC DE’s holdings in Johnson & Johnson were worth $125,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Prospector Partners LLC raised its holdings in shares of Johnson & Johnson by 15.9% in the fourth quarter. Prospector Partners LLC now owns 77,232 shares of the company’s stock worth $11,169,000 after buying an additional 10,585 shares during the last quarter. Garrison Point Advisors LLC increased its position in shares of Johnson & Johnson by 17.0% in the 4th quarter. Garrison Point Advisors LLC now owns 18,661 shares of the company’s stock valued at $2,699,000 after acquiring an additional 2,715 shares during the period. Federated Hermes Inc. grew its stake in Johnson & Johnson by 48.2% during the 4th quarter. Federated Hermes Inc. now owns 3,108,370 shares of the company’s stock valued at $449,532,000 after purchasing an additional 1,011,533 shares during the last quarter. Waterloo Capital L.P. raised its position in Johnson & Johnson by 11.7% during the 4th quarter. Waterloo Capital L.P. now owns 16,098 shares of the company’s stock worth $2,328,000 after buying an additional 1,681 shares during the last quarter. Finally, Ilmarinen Mutual Pension Insurance Co lifted its stake in Johnson & Johnson by 41.7% during the 4th quarter. Ilmarinen Mutual Pension Insurance Co now owns 356,600 shares of the company’s stock valued at $51,571,000 after acquiring an additional 105,000 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Timothy Schmid sold 403 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $153.03 on Monday. The firm has a 50-day simple moving average of $159.75 and a 200-day simple moving average of $155.76. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $368.77 billion, a price-to-earnings ratio of 23.01, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business’s revenue was up 5.3% on a year-over-year basis. During the same period last year, the company posted $2.29 EPS. On average, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on JNJ. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Citigroup lowered their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Wells Fargo & Company lowered their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $171.33.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.